NCT07566897 2026-05-05A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsPhilogen S.p.A.Phase 1 Not yet recruiting96 enrolled